| 영문 | activation | 한글 | 활성, 활성화 |
|---|---|---|---|
| 설명 | 일반적으로, 생체나 생체 물질이 그 기능을 활발하게 나타내게 되는 것, 예를 들면 ① 촉매 등에서, 그 표면 상태의 변화나, 다른 물질의 첨가 등에 의하여, 그 기능이 현저하게 높아지는 것. ② 효소전구체의 활성화로서 효소작용을 가지지 않는 효소 전구체가 활성있는 효소로 변화는 것. 또 황화수소나 시안화수소산 등으로 파파인이 활성화되는 경우도 있다. |
||
| 영문 | testicular feminization syndrome | 한글 | 고환여성화증후군 |
|---|---|---|---|
| 설명 | 이차성장을 포함하여, 외성기의 발육은 여성이지만 고환이 존재하고, 자궁과 자궁관이 결핍되어 있는 남성 거짓남녀한몸증의 극단적 형태이다. 이것은 테스토스테론의 작용에 대한 말단기관의 저항에 기인한다. |
||
| 영문 | irritable bowel syndrome | 한글 | 과민성대장증후군 |
|---|---|---|---|
| 설명 | 배변장애, 복통, 복부팽만 등의 증상이 있으나 기질적인 병변이 없음이 확인된 예를 총망라한 임상 증후군이다. 가장 흔한 소화기 질환이며(전소화기 환자의 70~80%) 가장 흔한 질병(전체 인구의 약 20%)이다. 여성이 남성에 비해 2배 정도 많이 발생하며 30대 및 40대에서 호발하고 선진 공업국에서 많이 발생한다. 진단을 위해서는 병력 청취가 가장 중요하고 각종 검사로서 기질병을 제외해야 한다. 치료로는 안정요법(정신과적 면담 및 심리요법, 신경안정제), 식사요법(고섬유질 음식 섭취, 자극성 음식 피하기), 약물 요법(창자경련 진정제, 변비 완화제, 지사제) 등을 사용한다. |
||
| 영문 | withdrawal syndrome | 한글 | 금단증후근 |
|---|---|---|---|
| 설명 | 알코올, 마약, 바비투르산계 최면약 등의 약물을 장기간 복용하여 약물이 없이는 견딜 수 없게된 뒤, 그 약물을 중지한 경우에 나타나는, 고통이 수반되는 신체적 증상을 말한다. 연속 복용의 기간에 따라 증상이 무거워진다. 통상적으로 구토, 설사, 혈압상승, 빠른맥, 땀남, 혼수 등의 증상이 나타난다. |
||
| 영문 | organic brain syndrome | 한글 | 기질적 뇌증후군 |
|---|---|---|---|
| 설명 | 뇌의 기질적인(organic-:이 말은 기능적인(functional)에 반하는 말로써) 모든 검사를 시행하면 어떤 이상을 발견할 수 있다는 뜻이다. 바꾸어 말하면, 기능적인 이상에 의한 뇌증후군은 어떠한 검사로도 이상을 발견할 수 없으나 분명히 환자에게 이상증상이 나타났을 때 이를 묶어서 말한다. 이상에 의해 신경학적인 이상을 나타내는 일련의 병적현상을 모두 통틀어 말한다. 이 병은 흔히 보아 마치 정신병환자처럼 말을 횡설수설하고, 알아들을 수 없는 말을 하며, 때로는 다른 사람에게 공격적인 성향을 나타내기도 한다. 그리고 다른 사람과 도저히 교류를 할 수 없는 정서를 나타내기도 한다. 그러나, 이 병이 다른 정신병과 구별되는 특징적인 증상은 먼저, 의식의 혼탁이 동반되는 경우가 많고, 또한 그 증상의 정도가 변한다는 것이다. 즉, 아침에는 정상적인 행동을 하다가 오후가 되면, 의식이 흐려지면서 말을 횡설수설한다면, 이는 기질성뇌증후군일 가능성이 높다. |
||
| MAF | macrophage activation factor; macrophage agglutinating factor; maximum atrial fragmentation; minimum... |
|---|---|
| MSF | macrophage slowing factor; macrophage spreading factor; Medicins sans Frontieres [Doctors without Bo... |
| PM | after death (Lat. post mortem); after noon [Lat. post meridiem]; mean pressure; pacemaker; pantomogr... |
| MS | Maffuci syndrome; maladjustment score; mandibular series; Marfan syndrome; Marie-Strumpell [syndrome... |
| CS | calf serum; campomelic syndrome; carcinoid syndrome; cardiogenic shock; caries-susceptible; carotid ... |
| MAF | Macrophage activation factor |
|---|---|
| Kact | Activation constants |
| AD | activation domain |
| AF-1 | Activation function 1 |
| AICD | Activation induced cell death |
| macrophage activation | The process of altering the morphology and functional activity of macrophages so that they become avidly phagocytic. It is initiated by lymphokines, such as the macrophage activation factor (maf) and the macrophage migration-inhibitory factor (mmif), immune complexes, c3b, and various peptides, polysaccharides, and immunologic adjuvants. (12 Dec 1998) |
|---|---|
| activated macrophage | A mature macrophage, in an active metabolic state, that is cytotoxic to tumour/target cells, usually following exposure to certain cytokines. Synonym: armed macrophage. (05 Mar 2000) |
| alveolar macrophage | Macrophage found in lung and that can be obtained by lung lavage, responsible for clearance of inhaled particles and lung surfactant. Metabolism slightly different from peritoneal macrophages (more oxidative metabolism), often have multivesicular bodies that may represent residual undigested lung surfactant. (18 Nov 1997) |
| alveolar macrophage elastase | <enzyme> Metalloproteinase found in human alveolar macrophages Registry number: EC 3.4.24.- Synonym: elastase, alveolar macrophage, metalloproteinase elastase, human macrophage metalloelastase, mmp12 gene product, mmp-12 gene product, mme gene product, macrophage metalloelastase (26 Jun 1999) |
| armed macrophage | A mature macrophage, in an active metabolic state, that is cytotoxic to tumour/target cells, usually following exposure to certain cytokines. Synonym: armed macrophage. (05 Mar 2000) |
| associated macrophage | A mature macrophage in an active metabolic state that is cytotoxic to tumour/target cells, usually following exposure to certain cytokines. (05 Mar 2000) |
| macrophage | Relatively long lived phagocytic cell of mammalian tissues, derived from blood monocyte. Macrophages from different sites have distinctly different properties. Main types are peritoneal and alveolar macrophages, tissue macrophages (histiocytes), Kupffer cells of the liver and osteoclasts. In response to foreign materials may become stimulated or activated. Macrophages play an important role in killing of some bacteria, protozoa and tumour cells, release substances that stimulate other cells of the immune system and are involved in antigen presentation. May further differentiate within chronic inflammatory lesions to epithelioid cells or may fuse to form foreign body giant cells or Langhans giant cells. (18 Nov 1997) |
| macrophage-1 antigen | An adhesion-promoting leukocyte surface membrane heterodimer. The alpha subunit consists of the CD11b antigen and the beta subunit of the CD18 antigen (antigens, CD18). The antigen, which is an integrin, functions both as a receptor for complement 3 and in cell-cell and cell-substrate adhesive interactions. (12 Dec 1998) |
| macrophage-activating factor | An agent that stimulates macrophages to attack and ingest cancer cells. They are secreted by stimulated lymphocytes that prime macrophages to become non-specifically cytotoxic to tumours. They also modulate the expression of macrophage cell surface ia antigens. One maf is interferon-gamma (interferon type II). Other factors antigenically distinct from ifn-gamma have also been identified. (12 Dec 1998) |
| macrophage colony-stimulating factor | <growth factor> A glycoprotein growth factor that causes the committed cell line to proliferate and mature into macrophages. A cytokine synthesised by mesenchymal cells that stimulates pluripotent stem cells of bone marrow into differentiating towards the production of monocytes (mononuclear phagocytes). The compound stimulates the survival, proliferation, and differentiation of haematopoietic cells of the monocyte-macrophage series. It is a disulfide-bonded glycoprotein dimer with a mw of 70 kD and binds to a single class of high affinity receptor which is identical to the product of the c-fms proto-oncogene. See: colony-stimulating factors. Chemical name: Colony-stimulating factor 1 Acronym: M-CSF (12 Dec 1998) |
| macrophage inflammatory protein | <cytokine> A chemokine that is chemotactic for neutrophils and monocytes, stimulates macrophages, and may play a role in regulating haematopoiesis. Its two variants, mip-1alpha and mip-1beta, are 60% homologous to each other. They are heparin-binding proteins that exhibit a number of inflammatory and immunoregulatory activities. Originally identified as secretory products of macrophages, these chemokines are produced by a variety of cell types including neutrophils, fibroblasts, and epithelial cells. They most likely also play a significant role in respiratory tract defenses. (20 Sep 2002) |
| macrophage inhibition factor | <cytokine> A group of lymphokines (including a 14 kD glycoprotein) produced by activated T lymphocytes that reduces macrophage mobility and probably increases macrophage macrophage adhesion. (18 Nov 1997) |
| macrophage migration inhibition test | A test which measures the presence of migration-inhibitory factor. Usually peritoneal macrophages are placed in a capillary tube in the presence or absence of supernatants from activated T-cells. If MIF is present, the migration of monocyte/macrophages is reduced. Synonym: macrophage migration inhibition test, migration inhibition test. (05 Mar 2000) |
| macrophage migration-inhibitory factors | Proteins released by sensitised lymphocytes and possibly other cells that inhibit the migration of macrophages away from the release site. The structure and chemical properties may vary with the species and type of releasing cell. (12 Dec 1998) |
| receptors, granulocyte-macrophage colony-stimulating factor | Receptors that bind and internalise the granulocyte-macrophage stimulating factor. Their mw is believed to be 84 kD. The most mature myelomonocytic cells, specifically human neutrophils, macrophages, and eosinophils, express the highest number of affinity receptors for this growth factor. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|